Levity: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinlevity.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and liraglutide drug products.

1. 1

   “The compounded semaglutide and liraglutide products displayed on your website identify “Levity” on the pictured label, suggesting Levity is the compounder of those drugs when in fact it is not.”

2. 2

   ““The same ingredient as Ozempic® + Wegovy®” “The power of Saxenda®””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

joinlevity.com returned a live storefront when we checked in August 2026, advertising a first month at a discounted rate with a published ongoing monthly price and listing branded Ozempic, Wegovy and Mounjaro as in stock.

Liraglutide is the reason this letter reads differently from the rest. It is the older daily GLP-1, and a compounded version of it is usually the cheapest injectable on a menu — which is exactly why the phrase FDA objected to matters. "The power of Saxenda®" does not say the product contains the same ingredient, does not cite a trial, and does not compare a price; it simply transfers a brand's reputation onto a cheaper item beside it. There is no factual claim there to check, which is what makes it effective and what FDA said makes it misleading. When a low-priced option is sold on a brand's borrowed reputation rather than on its own description, the price is the only thing on the page you can actually verify.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Levity failed to respond.